Print this page
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease
Protocol: 012313Principal Investigator:
- Amer Assal MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Multiple Myeloma -
A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy
Protocol: 112308Principal Investigator:
- Meenakshi Goyal-Khemka (Rutgers University)
Applicable Disease Sites: Leukemia, other -
A Phase 2 Study of SNDX-5613 in Combination with Chemotherapy for Patients with Relapsed or Refractory KMT2A-Rearranged Infant Leukemia.
Protocol: 112402Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Leukemia, other -
Community Engagement in Developing a Web-Based Single-Session Psychosocial Intervention for Adolescent Siblings of Youth with Cancer
Protocol: 132302Principal Investigator:
- Christina Amaro PhD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Other -
Pediatric Acute Leukemia (PedAL) Screening Trial: Developing New Therapies for Relapsed Leukemias.
Protocol: 112204Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Leukemia, not otherwise specified -
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol.
Protocol: 111706Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Any Site